Thursday, March 26, 2015

Payers, Personalization and Patients

Pin It Now!
This post is brought to you by our partner PharmiWeb Solutions and originally posted on their website.  PharmiWeb Solutions was born in November 2003 - the brainchild of a group of people who saw the benefits of bringing digital to pharma and healthcare. 

By: Avril Humphrey, Client Services Executive (US Office) 

Increasingly in the Pharma industry, we are seeing that the rather fixed mindsets that can result in frustration among digital marketers are being challenged by the evolving world of our customers and the consumers of our products. How can an industry stand still when there are new decision makers, new ways of sharing information and, critically, new ways of seeing how that information is being received by patients or physicians?

ePharma 2015 touched on all these topics and more, allowing speakers to present their experiences and insights into how we can navigate new territories or, at least, start to enter arenas which have so far been perceived as too risky. 

So, who are our payers, how are we targeting them and are we doing this effectively? The Affordable Care Act, part of wider Healthcare Reform, is cited as the most impactful change of recent years, and the effects are still being understood, including the influence on access to physicians and the consideration of a new customer segment of decision makers. As we consider the breadth of roles that now impact prescribing, we need to think about the content that is being promoted and how this is being done. This is where digital is integral to ensuring that the Pharma industry can stay relevant and adaptable. The tools in the field and online represent an opportunity to tailor your message across different channels and audiences; the data analysis tools above the field allow you to assess how successful your strategy is.

Tailoring your content and targeting your audience are essential to a strategy that presents the right people with what they want or need to see. We’re not in a position to create an experience for physicians, and they don’t necessarily want this – distinct from other industries, customers within Pharma are skeptical of the information they are being given and what they have to provide in return to see it. Within these limitations (and others), the only way to cut through the deluge of material available to, and directed at, physicians is to give them information that provides value, in a way that they want to see it. To do this, though, is to evolve the approach to content creation and distribution, as well as to navigate the complex course of federal and organizational approval systems and processes. Continuous analysis of the result of these efforts, however, makes it possible to gain a real return on the investment by evaluating and subsequently adapting tactics based on the evidence available.

As for the patient, can we accept the risk of evaluating their experience or creating a dialogue with them? Patients have opinions: they care about the drugs they are taking, how those drugs are making them feel and how those drugs are making other patients feel. The opinions of patients matter: an informed and supported patient is more likely to see the value in the medications they are prescribed, leading to better adherence and outcomes. Methods of opening up this communication with patients exist and there is a drive to use these from patient advocacy groups, as well as patients themselves and brand teams.  As Pharma continues to recognize the mutual value of this sort of engagement, and the qualitative results that can be gained, the commitment to new interactions signposts a promising trend towards transparency and consideration for the patient experience. 

As ePharma gave delegates an opportunity to see, digital is opening up better and more intelligent avenues to personalize the physician, payer and patient experience by providing the means through which we can target users, tailor content and appraise the results. It’s up to us to use it properly to reap the benefits.

Do you need help in creating your very own Digital Ecosystem? At PharmiWeb Solutions we help our customers understand what their customers want from a digital experience and deliver on this, from strategy and scoping to data & insights. Contact us to find out more.

Tuesday, March 24, 2015

Why You Should Sync Your CRM and Marketing Automation

Pin It Now!
By: Zach Watson, content manager, TechnologyAdvice

Disagreements between marketing and sales are well documented. More often than not, the two departments most responsible for fulfilling the needs of the customer can’t seem to get along.

What keeps the fires of their feud burning? Usually, misalignment and data silos. The bickering between sales and marketing often comes down to the quality of leads and the consistency of follow up. Marketing generates poor leads. Sales doesn’t follow up with enough opportunities to make an impact.

To get marketing and sales to stop bickering and start collaborating in a productive (and profitable) way, you need to make sure both parties have access to longitudinal data about their customers. In order to do that, you have to sync your marketing automation (MA) software with your customer relationship management (CRM) software.

Clarity Through Connection

Because marketing and sales are the two most customer-facing departments, it makes sense that their main software systems would hold the majority of customer information.

For sales, the CRM has long been the repository for lead and contact information, and it’s more recently become a type of operating systems for emails, social selling, and other important sales tasks.

The marketing automation platform is a less mature product, but it’s finding a place as a central hub for a number of marketing tactics that span email, social media, landing pages, pay per click marketing, and more. This wide range of functionality means these systems gather a tremendous amount of behavioral data.

Connecting the online behavioral data from a marketing automation system with the qualitative data in a CRM helps build a more holistic buyer’s journey, complete with data on leads throughout the funnel.

Better education. Better Leads.

Connecting these two systems is especially important for increasing revenue. MarketingSherpa reports that 61 percent of business-to-business marketers (which includes pharmaceutical and life science companies) pass every lead directly to sales despite only around 27 percent being qualified.
Talking to sales early in the purchasing cycle is contrary to how the majority of consumers — both business and personal — make decisions about products and services.

Postwire Founder and CEO Cliff Polan explains, “in the old world of sales, salespeople controlled the information. Today, all of the information is publicly available on the internet. The salespeople must now add value, because if salespeople aren’t adding value to the discussion, they’re losing.”

Consumers want educational material that helps them construct their own perception of the market. This reinforces the importance of marketing in the early stages of the funnel. For salespeople to remain relevant, they need to access and make use of the behavioral data generated from marketing automation to provide context for their conversations with leads.

Proper lead nurturing through educational marketing will also ensure that sales doesn’t intrude on the consumer when they’re still in the research phase. It takes some testing, but marketing should be able to use behavioral cues as a signal that a lead is ready to move to the next stage.

But this continuous buyer’s journey breaks down if sales can’t intuitively access the marketing data. Connecting the two systems is key to arming sales representatives with the context they need to address customers’ problems in a meaningful way.

Measurable Marketing ROI

Just as sales benefits from accessing a customer’s online behavioral data to clarify and confirm what they’re interested in, marketing enjoys a greater understanding of the success of their campaigns by accessing data from the CRM.

Since CRMs often record revenue data on a per-sale basis, marketing can quickly tie that information to a lead’s profile and segment campaigns based on number of deals closed, or actual revenue.

This may seem like an obvious goal for every organization, but being apparent doesn’t equate to being easy. Only 21 percent of B2B marketers say they excelled at measuring ROI in 2014. Many of them were not thinking of ROI in terms of revenue.

Aligning sales and marketing has key strategic benefits for both intra office morale as well as revenue. With the growing prominence of marketing automation, businesses now have an endpoint with which to connect the CRM.

Fusing these two databases breaks down information silos and creates a more complete view of the customer that benefits all parties. When selecting marketing automation software, be sure to look for integration with popular CRMs, or at the very least API availability that enables easier interface development.

About the Author: Zach Watson is the content manager at TechnologyAdvice. He covers gamification, healthcare IT, business intelligence, and other emerging technology. Connect with him on LinkedIn.

Tuesday, March 10, 2015

Millennials and the New Health Revolution

Pin It Now!
Preventative Health is Best Thought of When You Don’t Have to Think About It

An apple a day keeps the doctor away. Unfortunately paying tribute to this age old adage in practice can be a lot more difficult for most of us than it sounds. Our healthcare system could be better described as a great sick care system, with only a fraction of resources focusing on preventative health measures. 

But here come the Millennials who will infuse new life into the wellness and preventative care sphere, and will be the first cohort fully immersed in real time health monitoring. From disrupting the boundaries of traditional health and forcing stakeholders to rethink healthcare delivery, Millennials are also shifting the notion of preventive health and what it means to be healthy. For them, health inextricably goes beyond weight loss or avoiding a visit to the clinic. It’s about emotional wellbeing and leading a balanced lifestyle and perhaps more fundamentally, it’s about everyday decisions. These perceptions are rooted in an utter dissatisfaction for the healthcare system we have today-inefficient, expensive and impersonalized. Part of the new appeal for wellness is anchored in watching their elders, from diagnosis to treatment, traverse an often cumbersome, paternalistic, and choice limited healthcare journey.

We talk about the shift towards delivering better patient experiences and outcomes in healthcare. The wearables market will underpin these value propositions, introducing real time health monitoring in almost every aspect of your daily life.  As the patient becomes more empowered with millions of personalized data points, getting patients to share data could be a barrier to effective implementation of real time monitoring. Thankfully, the Millennial generation is amenable to sharing, and that will include health experiences. Whether you choose to share with your clinician, friends, or family will lead to the emergence of a new health revolution where wellness is just as important as health. It’s more about searching for an enriching healthcare experience and switching life health coaches if you don’t like what you are dealt with.  

Wellness communities will emerge, led and followed on Twitter, Instagram and WhatsApp, including groups from stress reduction to yoga and mindfulness, and from nutrition to fitness challenges. This movement will also help establish social proof and lead to the more widespread adoption of preventative health as integral mantra of one’s lifestyle. Preventative health shouldn’t be extra work, and as wearables form a key layer in our personal space, more engagement in wellness activities will be as common. Deeper insight is great, but insight without lack of actionable context and behavioral change is almost as useful as having a car without an engine. The most successful health stakeholders in this new health revolution will be able to engage and induce behavioral change.

The traditional boundaries of healthcare are slowly eroding as millennials engage in new spheres of health engagement and where health will be projected onto everything you do. As the delivery of healthcare takes place more and more outside traditional institutions, the new social norm will shift towards the establishment of a reward system for the maintenance and promotion of health. Millennials are breathing new life into wellness and prevention, and new horizons for stakeholders interested in providing enriching health experiences await-are you ready?

About the Author: Aaron Sihota is an award winning pharmacy innovator and recently hosted a webinar for the ePharma Summit  discussing emerging healthcare trends and opportunities for healthcare provider engagement for a younger health consumer generation. He has a keen interest in the application of innovative solutions to address today’s healthcare issues and actively promotes community pharmacy practice initiatives. He is a recent graduate of the University Of British Columbia Faculty Of Pharmaceutical Sciences. 

Wednesday, March 4, 2015

Digital Impacts Improving Patient/Doctor Relations

Pin It Now!
Digital impacts on consumer insights have grown more vital in improving customer inclusion. Disruptive innovations are becoming paramount to improving consumer experience. These innovations span a wide variety of fields and a recent system has been introduced to the healthcare industry that has revolutionized patient involvement, physician time management and the health of patients.

Collabobeat, the brainchild of Italian entrepreneur Floriano Bonfigli, is a system designed to share doctor’s notes with their patients. The patient then can use the system to see what the doctor recommended when home in case they had either forgotten or weren’t clear on what was instructed. In the US alone, billions of dollars are wasted due to patients not following their doctors instructions. Thousands of patients become ill or potentially worse as a result.

The system has been trialed at 3 American hospitals involving 100 physicians and 10,000 patients. The results in general showed a huge success for the system. It was found that there was a 70 percent increase in patient medical adherence which leads to improved results in patient recovery. The results also showed that 92 percent of the doctors spent less time addressing patient’s questions outside of consultations. This platform for increased connection with the patient helps to give them a sense of involvement and empowerment. It stops information from the physician getting lost in translation as the ability to comment on and reread doctors notes means less of a chance for the patient to get instructions wrong, thus not putting themselves in harm’s way.

The system will be integrated into other software that is already utilized in the healthcare industry. The merging in of the system allows patients in time information at their fingertips that allows for a better relationship between patient and doctor. A strong relationship between industry and consumer is important in making the service feel more personal to the consumer.

Innovations like these show the greater need for consumer interaction that will improve experiences across industries. Better physician and patient relationships can translate into other fields such as retail whereby increasing the amount of information that is available for the consumer helps with their decision making and thus giving them a better retail experience.

Information is key to improved customer insights and digital impacts are increasingly improving the way in which industries and consumers interact. Personalization is key to making the customer feel more involved and having as much knowledge as possible about what they need. In a world that is becoming increasingly mobile and interconnected, digital innovations are becoming more important for the future of consumer insights.

About the Author: Harry Kempe, a marketing intern at IIR USA, who works on various aspects of the industry including social media, marketing analysis and media. He is a recent graduate of Newcastle University who previously worked for EMAP Ltd. and WGSN as a marketing assistant on events such as the World Architecture Festival, World Retail Congress and Global Fashion Awards. He can be reached at

Thursday, February 26, 2015

Patient Engagement and Improving the Lines of Communication

Pin It Now!

Today, representatives from WEGO Health, Janssen US, HealthPrize, and The Great BowelMovement participated in a panel discussion to talk about the issues related to patient listening and engagement- how to capture patient voice, improve medication adherence, and work with online patient communities and activists.

The consensus among the panelists and participants was that patients need to be given the opportunity to define themselves- their needs, preferences, emotional state, and barriers in order for pharma to understand what role it can play within patient communities. As Todd Kolm from WEGO Health put it, “You won’t know if you don’t ask.”

Pharma Engagement with the Inflammatory Bowel Disease Community
In order to effectively support patients, Jennifer Thomas of Janssen US said that pharmaceutical companies and others must listen to the needs of the community, look deep to find hidden truths, and lead patients to credible information.

Over the past several years, Janssen has taken great strides to engage with patients. “We did a lot of listening to patients around the time that the FDA released its guidance on social media,” Thomas said.

Working with Crohn’s disease and ulcerative colitis patients, Janssen found a really passionate group of people. “That’s where we started to really uncover what their needs are [in order to] hopefully engage with and bring value to them,” Thomas said.

Through it’s listening, Janssen uncovered themes within online discussions among IBD patients- treatments, daily living, and more. They also discovered a lot of confusion among patients, bad advice, and frustration.

“[We learned that] branded marketing messages were not the way that we were going to move the needle for the IBD patient community,” Thomas said.

Janssen developed a panel of Crohn’s disease and ulcerative colitis activists to uncover online needs and perceptions in order to help shape key messaging and materials.

Thomas offered a piece of advice for other pharmaceutical companies preparing to embark on similar listening ventures. “Be ready to hear honest and real feedback, incorporate suggested changes, and to fall in love with the patient community. It’s a powerful way to bring what you do to life.”

Engaging Patients to Improve Medication Adherence
A neurosurgeon by training and former practice, Dr. Katrina Firlik of HealthPrize is looking at human psychology to understand what makes people take or not take medication.

Dr. Firlik embarked on research into medication adherence and non-adherence based around some sobering statistics:
-       In the United States, medication non-adherence accounts for $290 billion spent in otherwise avoidable medical costs
-       25 percent of new prescriptions are never filled
-       50 percent of new patients quit refilling their scripts within 12 months

For years, medication non-adherence was attributed to either high costs or patient forgetfulness. However, a study in the New England Journal of Medicine yielded other reasons that patients did not take their medication:
“I’ve never been a pill person.”
“I don’t believe in them.”
“If there is a lawsuit out there about side effects, I’m not taking it.”
“I don’t like taking medication, period.”
“I’m old-fashioned. I don’t take medicine for anything.”

Looking at similar studies, Dr. Firlik and her team at HealthPrize concluded that providers and pharmaceutical companies need to find a way to make the medication taking process more positive. HealthPrize created short-term rewards, which yielded high engagement rates because of the instant gratification patients receive.

Rewards aren’t the end all be all for medication adherence. Dr. Firlik said that the benefits of taking medication need to be better communicated. “[Being on] medication can impose a sick identity antithetical to how a patient feels,” she said. “A positive metaphor or visual can help express a medication’s benefit. We need to leverage the power of personal testimony and videos.”

The negatives of non-adherence also need to be communicated more effectively. Dr. Firlik suggested that virtual reality could be used to show patients the impact of taking medication to manage an illness versus not taking the medication. This would provide patients with a realistic look at their illness and make better decisions about their treatment plan.

Patient Perspective on Engagement
Andrea Meyer grew up in a highly regimented family- everything was planned out. But in 2001, her life was flung into inconsistency. The co-founder of the Great Bowel Movement said she went through months of debilitating pain, weight loss and hair loss.

“College is when it came to a head,” Meyer said. “After my 21st trip to the bathroom in a 24 hour period, I decided I was done with loss. I needed to know what was wrong. I wanted to gain things again- knowledge and hope- and I wanted a plan.”

Meyer was diagnosed with Crohn’s disease and about seven years ago, had surgery to remove part of her intestines. Once she was recovered and healthy, she decided she needed to do something useful and set forth on her path to becoming an advocate.

“When you’re chronically ill, you have to learn how to be a patient for the rest of your life,” Meyer said. “You can’t see a finish line.”

She said patient engagement is key to giving chronically ill patients some sense of control back into their lives. “When someone is first diagnosed [with a chronic illness], there is a sense of being victimized. Asking someone to be engaged gives him or her a piece of control back. That’s huge,” she said. “Patients are like horses- they are going to spook easily and will respond best to repetition and consistency.  Once you reach out to them, they are going to look to you to lead the way.”

For pharmaceutical companies and others looking to build relationships with an online patient community, Meyer says that authenticity is important. “Nothing spreads faster than genuine reliable content.”

So what do patients want from pharmaceutical companies? According to Meyer, “complimentary services and information that go hand-in-hand with drugs and procedures. Patients are big sponges. If the information is there (and it should be), we are going to take advantage of that.”

Additionally, she cautioned pharma to maintain a presence once they begin engaging. “We want to know we’re headed somewhere together- don’t just survey the community and disappear,” Meyer said. “We want to know where everything is going.”

While a social media presence is a must, Meyer ended by cautioning pharma from trying to do too much. “Don’t be a diner,” she said. “You don’t have to do everything. Pick a couple of things and do them well; don’t do everything mediocre. It will pay off leaps and bounds.”

About the author:
Rebecca Kaplan is a communications consultant, freelance writer, and blogger. You can read more about her life loving someone with Crohn's disease on her blog, on Huffington Post, or follow her on Twitter

Turning Underdog Brands into Overachievers

Pin It Now!
Closing out ePharma Summit 2015 this afternoon in New York City, Bill Drummy, CEO of Heartbeat Ideas, talked to us about turning underdog brands into overachievers.

If you are an underdog, you have to overcome a lot of skepticism and obstacles. Many of us see ourselves as “the underdog.” On the other hand, there’s very little resonance with “the top dog.”
The underdog effect impacts the pharma industry in many ways. The underdog brand struggle includes less money, fewer resources, but must quickly prove success.

What is the behavior of an underdog that causes overachieving? You have to think different, be bold and stand out, you have to move really quickly, and you have to use tools in an innovative way.
Some examples of underdog marketing campaigns outside the pharma industry include K-Mart’s “Ship Your Pants” campaign and Dos Equis “Most Interesting Man in the World” campaign, which were both highly successful almost immediately.

In the pharma industry, a brand called Sientra has been a successful underdog because it thinks with absolutely clarity. It created new marketing campaigns targeting plastic surgeons and consumers. In turn, these successful brand marketing campaigns caused Sientra to go from nothing to an IPO in just over two years.

In addition, a brand called Testin created another successful campaign that launched it into success after speaking directly to the male consumer about low testosterone through TV and web by using humor and unique creative.

Overall, underdog brands in the pharma industry today can become market leaders by adding creativity and innovation into their marketing and advertising campaigns.

About the Author: Amanda Ciccatelli, Social Media Strategist of the Marketing Division at IIR USA, has a background in digital and print journalism, covering a variety of topics in business strategy, marketing, and technology. Amanda is the Editor at Large for several of IIR’s blogs including Next Big DesignCustomers 1stDigital Impact, STEAM Accelerator and ProjectWorld and World Congress for Business Analysts, and a regular contributor to Front End of Innovation and The Market Research Event,. She previously worked at Technology Marketing Corporation as a Web Editor where she covered breaking news and feature stories in the technology industry. She can be reached at Follow her at @AmandaCicc.

Is 2015 the year Pharma "Likes" Social?

Pin It Now!
In 2014 the FDA finally began to carve out a position on social media. While the current guidance is far from complete, we are beginning to see definition around some of the key areas in social media where pharma would like to play. With a more definitive set of guidelines, expected to be released in the coming months (fingers crossed), the road forward for pharma in social media could become a little clearer.

This is an exciting prospect, but how ready is pharma for social, really? While some companies have been way ahead of the curve, many are just starting to think about social media as a viable channel. We’re getting there! But for those who are just beginning to test the waters, what should you be thinking about?


1. User-generated Content
Commenting, sharing, re-tweets…it can all seem a little overwhelming to manage. The good news is that the FDA will not hold brands accountable for social content that is deemed “truly independent”. This will likely free brands from direct responsibility for comments posted on or to their social channels, which allows for a more genuinely “social” interaction with users.

However, fear of negative brand comments and adverse event (AE) reports are often one of the biggest hurdles for pharma marketers to overcome as they prepare their organization to launch a social media channel or campaign. In fact, valid AE reports are extremely rare in social media—a recent study found only 0.3% of social posts contained an actionable AE. As for negative comments, the best thing a brand can do is be prepared to get ahead of a potential problem. Negative conversations will likely happen with or without you, so put processes in place to proactively address issues if/when they come up.

Takeaway: Think through every possible issue and develop a detailed response plan and protocol to prepare for user comments.

2. Fair Balance Requirements
Social media can be especially complicated for branded pharma communications because of fair balance requirements. Most social platforms are set up to deliver micro-communications that are structured around character limitations (eg, Twitter’s 140-character count). The FDA requires any brand message that includes both brand name and indication to carry the full fair balance. Posting the fair balance prominently on a brand’s social channel isn’t enough, especially when you consider that most social posts are viewed as part of a feed and not on the brand’s homepage.

Some pharma brands have gotten around this rule by creating branded social platforms that never mention the disease they are indicated to treat. While this can be somewhat effective if the brand name is well recognized, there isn’t much value for the user in Tweets or Facebook posts from a brand that can’t actually talk about what it does or the condition it treats.

Takeaway: As long as fair balance requirements remain as is, branded pharma communications in social media may not be worth the level of effort required to make them happen.

3. Internal Regulatory Preparedness
In many cases, ambitious or innovative ideas don’t make it through the medical/legal regulatory review phase. Due diligence is an important part of the process, so how do we manage regulatory concerns while also maintaining the essence of a social experience?

First, be realistic about what’s possible in a regulated environment. While it can often be creatively rewarding to push boundaries, it’s important to acknowledge that there are certain things we just won’t be able to say. Be mindful of where the roadblocks are and push your teams to think around them, not ignore them.

Second, in many cases, regulatory teams have little or no familiarity with the social media space. Sure, they’re probably using Facebook but they have likely never really thought about how social platforms work or what types of guardrails can be put in place to help pharma brands remain compliant with FDA regulations. Instead of throwing your hands up in the air and wailing about mean old regulatory, take some time to work with them to explain how each social media platform works and how you intend to manage it.

Takeaway: Make it your mission to help educate regulatory teams— it’s amazing what a difference this can make!

4. Planning and Resources
Once you’ve cleared the way to move forward with social media, how do you actually make it happen? An effective social media strategy includes meticulous editorial and engagement planning, as well as ongoing channel management. One of the biggest mistakes we see brands make is launching one or more social media channels without considering the need for a plan or a community manager. You’ll likely be able to spot these unmanaged channels in a couple of ways: 1) They post sporadically (some laying dormant for months or even years) 2) The channel content is almost entirely self promotional.

Don’t lose sight of the fact that it’s called social media for a reason. A brand should establish a unique voice and presence, interact with users (even if only occasionally), monitor the conversation and deliver compelling content that users are interested in. This takes time and effort. Don’t assume that you can get away with letting the channel run itself.

Takeaway: Community Management is a full-time job and it is well worth the investment.

Social Media is more than just a passing fad, it’s now firmly established as a valuable communications tool. With guidance becoming clearer for pharma, now is the time to explore what’s possible!

About the Author: Sarah Campbell is the SVP Group Director of Digital Activation at McCann HumanCare, an integrated health & wellness communications agency that’s part of McCann Worldgroup. Connect with us on LinkedIN.

Daiichi Sankyo & Partners Healthcare Center for Connected Health Use Mobile Techn to Increase Engagement

Pin It Now!
This morning at ePharma Summit 2015 in New York City, Greg Barrett, vice president of marketing at Daiichi Sankyo Pharmaceuticals and Joseph Kvedar, director of the Center for Connected Health/Partners Healthcare talked to us about how they worked together to leverage mobile technologies to increase engagement.

Since the 1960s, the United States has been awarded more Nobel Prizes in medicine than the rest of the world combined. So, with all of this brilliance and investment, why is it that the NIH looks at the U.S. and it consistently performs at the bottom year after year. Things like this don’t change unless you change the dollars behind the equation. “We have to address quality and efficiency in U.S. healthcare,” the speakers said.

In fact, The Affordable Care Act has created significant shifts in our healthcare system. The pharma industry has to address quality and efficiency to address these shifts. “We are moving towards value-based reimbursement in our healthcare system.”

So, how does the pharma industry move beyond the pill? There are two options: bundle with therapeutics or compete with yourself, according to the speakers.

As the pharmaceutical landscape continues to evolve, with a lot of new customer types, a shift in how health care is being delivered and the opportunity to leverage new technologies, Sankyo saw an opportunity to increase patient engagement.  In the Fall of 2014, Sankyo and the Center for Connected Health announced a partnership to create a coaching platform that engages patients in their care and supports behavior change with the ultimate goal of improving patient health.

Their new program is intended to improve the patient engagement and patient-provider dialogue. We learned how they are harnessing mobile and taking a “pill-plus” mentality, and hear the feedback they’ve received on this innovative programming from HCPs and patients thus far.

About the Author: Amanda Ciccatelli, Social Media Strategist of the Marketing Division at IIR USA, has a background in digital and print journalism, covering a variety of topics in business strategy, marketing, and technology. Amanda is the Editor at Large for several of IIR’s blogs including Next Big DesignCustomers 1stDigital Impact, STEAM Accelerator and ProjectWorld and World Congress for Business Analysts, and a regular contributor to Front End of Innovation and The Market Research Event,. She previously worked at Technology Marketing Corporation as a Web Editor where she covered breaking news and feature stories in the technology industry. She can be reached at Follow her at @AmandaCicc.

Patient Engagement in a Changing Ecosystem—How Expectations Are Changing for All Stakeholders

Pin It Now!
This morning at ePharma 2015 in New York City, Jeremy Shepler, patient-centered strategy and solutions at Novo Nordisk, took the keynote stage to discuss how patient engagement in a changing ecosystem is changing expectations for all stakeholders in the pharmaceutical industry.

The ACA has been a catalyst for a dramatic shift in the healthcare landscape toward more empowered patients and more powerful payers, potentially upending the way we market our products.  But, there is a big gap between cost and quality of United States healthcare. Today the U.S. outpaces other countries in cost, but not outcomes. In fact, almost one out of every five dollars is spent on healthcare in the U.S. This is not sustainable, period, according to Shepler.

“This is the challenge that we all face and this is causing the model in the pharmaceutical industry to change dramatically,” he explained.

Today, engaging patients is critical to improve health outcomes and improve system costs. This challenge leads to a huge and complex issue that we’ve been talking about for years – patient adherence. A new level of support must address the unmet needs of multiple constituents.

Currently, the pharma industry is shifting its focus very slowly, but it is working to become more customer-centric.  Patient empowerment is not dead, but we have to have a more deliberate focus on our customers, not just ourselves.

Are we structured to do this? Perhaps it’s not about structure, according to Shepler. Instead, maybe it’s about our mindset. If we are going to change this, it has to change at the top of our organizations. He said, “This change is not going to be easy and it’s going to take time.”

About the Author: Amanda Ciccatelli, Social Media Strategist of the Marketing Division at IIR USA, has a background in digital and print journalism, covering a variety of topics in business strategy, marketing, and technology. Amanda is the Editor at Large for several of IIR’s blogs including Next Big DesignCustomers 1stDigital Impact, STEAM Accelerator and ProjectWorld and World Congress for Business Analysts, and a regular contributor to Front End of Innovation and The Market Research Event,. She previously worked at Technology Marketing Corporation as a Web Editor where she covered breaking news and feature stories in the technology industry. She can be reached at Follow her at @AmandaCicc.

Wednesday, February 25, 2015

Integrating Digital Marketing with Field Force Engagements

Pin It Now!
This afternoon at ePharma 2015 in New York City, Brian McHale, Enterprise Multi Channel Marketing, Global Commercial Operations at Pfizer, talked to us about integrating digital marketing with field force engagements.

Ideally, sales forces and digital marketing materials will have a synergistic effect on promotion, providing HCPs with face-to-face relationships and digital information. Over the years, the numbers of sales pharma sales representatives have decreased, but the nature of who and what this field rep is, is changing and their responsibilities are changing.

Today, in most of the major markets around the globe the sales force continues to be the major investment for pharma. The impact of relationship generates sales. Often the relationship is a sales generator.

So, how do we make the most out of the sales force as a significant pharma investment?

For example, McHale and his team at Pfizer launched a rep triggered email strategy to integrate marketing and field force. This strategy allowed reps to enhance their relationship with the physician by providing timely and impactful resources and information via email. It also enables reps to communicate with customers in a manner that is aligned with how customers engage with information today. This strategy increases between HCPs and brands and drives “pull through” of other MCM programs.

About the Author: Amanda Ciccatelli, Social Media Strategist of the Marketing Division at IIR USA, has a background in digital and print journalism, covering a variety of topics in business strategy, marketing, and technology. Amanda is the Editor at Large for several of IIR’s blogs including Next Big DesignCustomers 1stDigital Impact, STEAM Accelerator and ProjectWorld and World Congress for Business Analysts, and a regular contributor to Front End of Innovation and The Market Research Event,. She previously worked at Technology Marketing Corporation as a Web Editor where she covered breaking news and feature stories in the technology industry. She can be reached at Follow her at @AmandaCicc.